(NASDAQ: KMDA) Kamada's forecast annual revenue growth rate of 8.79% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.85%.
Kamada's revenue in 2025 is $160,953,000.On average, 2 Wall Street analysts forecast KMDA's revenue for 2025 to be $10,396,909,605, with the lowest KMDA revenue forecast at $10,350,905,580, and the highest KMDA revenue forecast at $10,442,913,630. On average, 3 Wall Street analysts forecast KMDA's revenue for 2026 to be $11,301,463,742, with the lowest KMDA revenue forecast at $11,046,141,405, and the highest KMDA revenue forecast at $11,455,002,175.
In 2027, KMDA is forecast to generate $11,918,205,200 in revenue, with the lowest revenue forecast at $11,722,400,569 and the highest revenue forecast at $12,114,009,830.